Neuromyelitis Optica Spectrum Disorders clinical trials at UCSD

1 research study open to eligible people

Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
open to eligible people ages 2-17
A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to < 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin [Ig]G).
La Jolla, California and other locations

Last updated: June 4, 2025

Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder